The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1026
May 8, 1998
View Complete Issue         Table of Contents 2019 
Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
May 8, 1998 (Issue: 1026)
Dolasetron (Anzemet - Hoechst Marion Roussel), a selective serotonin (5-HT3) receptor antagonist similar to ondansetron (Zofran) and granisetron (Kytril - Medical Letter, 36:61, 1994) is now available for both oral and intravenous use in prevention...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
Article code: 1026c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.